{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T08:10:20Z","timestamp":1756282220518,"version":"3.44.0"},"reference-count":34,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T00:00:00Z","timestamp":1664928000000},"content-version":"unspecified","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2022,9,17]]},"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:p>Despite advances and introduction of new therapies in the last decade, metastatic castration-resistant prostate cancer (mCRPC) has a poor prognosis. The development of androgen axis-targeted therapies such as abiraterone acetate, enzalutamide and darolutamide can prolong survival in mCPRC; however, resistance remains a barrier to prolonged response, necessitating exploration into resistance mechanisms and locoregional therapies. Here, we describe a patient with mCRPC that was progressing on abiraterone acetate. He was also found to have primary hyperaldosteronism from a functional adrenal adenoma, and thus he had a partial adrenalectomy to remove this tumour. Pathology confirmed an aldosterone-producing adrenal adenoma. After his adrenalectomy, he had a sharp decline in both his PSA (prostate specific antigen) and testosterone levels, and he enjoyed a year-long period of remission after his adrenalectomy. We propose several explanations for his response, the most likely being that his adenoma was producing both aldosterone and androgens. This is a unique case of mCRPC responding to partial adrenalectomy from a functional adrenal adenoma, and it raises insights that warrant further investigation into underlying mechanisms of resistance to androgen-targeted therapies.<\/jats:p>","DOI":"10.1136\/bcr-2022-251036","type":"journal-article","created":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T11:56:22Z","timestamp":1664970982000},"page":"e251036","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Remission of progressive metastatic castration-resistant prostate cancer during abiraterone therapy following unilateral adrenalectomy for a functioning adrenal adenoma"],"prefix":"10.1136","volume":"15","author":[{"given":"Katelyn Nazaneen","family":"Seale","sequence":"first","affiliation":[{"name":"Department of Medicine, Duke University, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew K","family":"Labriola","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University, Durham, North Carolina, USA"},{"name":"Division of Medical Oncology, Duke Cancer Institute, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyin \"Sara\"","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Duke University, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University, Durham, North Carolina, USA"},{"name":"Division of Medical Oncology, Duke Cancer Institute, Durham, North Carolina, USA"},{"name":"Duke Cancer Institute, Center for Prostate and Urologic Cancer, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,10,5]]},"reference":[{"key":"2025082700371086000_15.10.e251036.1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clgc.2016.08.018","article-title":"Predicting time from metastasis to overall survival in castration-resistant prostate cancer: results from search","volume":"15","author":"Moreira","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"2025082700371086000_15.10.e251036.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.04.061"},{"key":"2025082700371086000_15.10.e251036.3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1625"},{"key":"2025082700371086000_15.10.e251036.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2009.03.016"},{"key":"2025082700371086000_15.10.e251036.5","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-10-0339"},{"key":"2025082700371086000_15.10.e251036.6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2019.105506","article-title":"The role of adrenal derived androgens in castration resistant prostate cancer","volume":"197","author":"Barnard","year":"2020","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2025082700371086000_15.10.e251036.7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1431"},{"key":"2025082700371086000_15.10.e251036.8","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4000"},{"key":"2025082700371086000_15.10.e251036.9","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-194512260-00012"},{"key":"2025082700371086000_15.10.e251036.10","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0022-5347(17)60911-X","article-title":"Bilateral adrenalectomy for palliative treatment of prostatic cancer","volume":"108","author":"Mahoney","year":"1972","journal-title":"J Urol"},{"key":"2025082700371086000_15.10.e251036.11","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0022-5347(17)67908-4","article-title":"Bilateral adrenalectomy for carcinoma of the prostate gland","volume":"70","author":"Baker","year":"1953","journal-title":"J Urol"},{"key":"2025082700371086000_15.10.e251036.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-018-0077-y"},{"key":"2025082700371086000_15.10.e251036.13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.biopha.2018.02.067","article-title":"Abiraterone acetate in the treatment of prostate cancer","volume":"101","author":"Thakur","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"2025082700371086000_15.10.e251036.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014618"},{"key":"2025082700371086000_15.10.e251036.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001294"},{"key":"2025082700371086000_15.10.e251036.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2025082700371086000_15.10.e251036.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022485"},{"key":"2025082700371086000_15.10.e251036.18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01035"},{"key":"2025082700371086000_15.10.e251036.19","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051517-011947"},{"key":"2025082700371086000_15.10.e251036.20","first-page":"798","article-title":"Evaluation of an adrenal mass in a patient with progressive prostate cancer reveals pheochromocytoma","volume":"13","author":"Alikhan","year":"2006","journal-title":"Int J Urol Off J Jpn Urol Assoc"},{"key":"2025082700371086000_15.10.e251036.21","article-title":"Castration failure in prostate carcinoma due to a functioning adrenocortical carcinoma","volume":"2021","author":"Navani","year":"2021","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"2025082700371086000_15.10.e251036.22","first-page":"101229","article-title":"Durable biochemical response following adrenal metastasectomy for oligometastatic castrate-resistant prostate cancer","volume":"32","author":"Ashrafi","year":"2020","journal-title":"Urol Case Rep"},{"key":"2025082700371086000_15.10.e251036.23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.9749"},{"key":"2025082700371086000_15.10.e251036.24","doi-asserted-by":"publisher","DOI":"10.1038\/pcan.2014.27"},{"key":"2025082700371086000_15.10.e251036.25","doi-asserted-by":"publisher","DOI":"10.1096\/fj.15-275552"},{"key":"2025082700371086000_15.10.e251036.26","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.2020.34.s1.09466"},{"key":"2025082700371086000_15.10.e251036.27","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1111\/bcp.14568","article-title":"Impact of spironolactone exposure on prostate cancer incidence amongst men with heart failure: a Pharmacoepidemiological study","volume":"87","author":"Hiebert","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2025082700371086000_15.10.e251036.28","doi-asserted-by":"publisher","DOI":"10.1016\/0022-4731(88)90295-6"},{"key":"2025082700371086000_15.10.e251036.29","doi-asserted-by":"publisher","DOI":"10.1136\/bcr.11.2011.5238"},{"key":"2025082700371086000_15.10.e251036.30","article-title":"Potential negative pharmacodynamic interaction of spironolactone and abiraterone in two prostate cancer patients","author":"Vicente-Valor","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"2025082700371086000_15.10.e251036.31","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/17843286.2018.1543827","article-title":"Abiraterone and spironolactone in prostate cancer: a combination to avoid","volume":"74","author":"Dhondt","year":"2019","journal-title":"Acta Clin Belg"},{"key":"2025082700371086000_15.10.e251036.32","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/j.clgc.2016.08.006","article-title":"Case report: spironolactone withdrawal associated with a dramatic response in a patient with metastatic castrate-resistant prostate cancer","volume":"15","author":"Flynn","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"2025082700371086000_15.10.e251036.33","doi-asserted-by":"publisher","DOI":"10.4076\/1757-1626-2-8951"},{"key":"2025082700371086000_15.10.e251036.34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF03349703","article-title":"Aldosterone and testosterone producing adrenal adenoma in childhood","volume":"18","author":"Schmitt","year":"1995","journal-title":"J Endocrinol Invest"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2022-251036","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T07:37:21Z","timestamp":1756280241000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2022-251036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":34,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10,5]]},"published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1136\/bcr-2022-251036"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2022-251036","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}